You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

Article metrics

Article menu
Basic tumor immunology
Original research
Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

 

Online download statistics by month:

Online download statistics by month: October 2023 to March 2026

AbstractFullPdf
Oct 2023534538174
Nov 2023531532142
Dec 2023455461154
Jan 202415815969
Feb 202417017039
Mar 202411511796
Apr 202410610752
May 2024737440
Jun 2024858556
Jul 20248183164
Aug 2024596079
Sep 20246061162
Oct 20249697174
Nov 202411111253
Dec 202410710838
Jan 2025939444
Feb 2025999944
Mar 2025676740
Apr 2025797943
May 2025525328
Jun 2025565827
Jul 2025110
Dec 2025550
Mar 2026110
Total319432211718